HOME >> MEDICINE >> NEWS
Italian researchers find fenretinide cuts the risk of second breast cancers in young women

A 15-year follow-up of women in a breast cancer trial has found that fenretinide[1] a drug related to vitamin A significantly cuts the risk of a second breast cancer among younger patients.

The Italian research team reporting the findings on-line (Thursday 4 May) in Annals of Oncology[2], are sufficiently convinced of the drug's protective potential to call for a trial to test its use as a preventive in pre-menopausal healthy women at high risk of the disease. They are now seeking international partners and funding for such a trial.

The women in the long-term follow-up comprised a sub-group of 1,700 60% of the patients in a 10-centre trial lead by Professor Umberto Veronesi and co-ordinated by Milan's Istituto Nazionale Tumori when he was its director. The study, which began in 1987, randomised more than 2,800 women to receive 200 mg fenretinide daily for five years or no extra treatment after surgery for early-stage breast cancer.

The new analysis, also lead by Professor Veronesi, who is now Director of the European Institute of Oncology in Milan, followed the 1,739 patients who had been recruited by the Istituto Nazionale Tumori centre, investigating whether these patients developed a second cancer either in the treated breast or the other breast.

Co-author Dr Andrea Decensi, Director of the Department of Medical Oncology at the Galliera Hospital in Genoa, said: "We followed these patients for between 12 and 16 years and we found 168 second breast cancers in the fenretinide arm and 190 in the control arm. In post-menopausal women there were actually more cancers in the fenretinide arm than among the controls (85 as against 64). But, among pre-menopausal women there were only 83 second cancers in the fenretinide group compared with 126 in the control group.

Dr Decensi said that overall, this meant a 17% reduction in second cancers among the fenretinide group, which was of borderline statistical significance. But, there we
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-015-367-72181
European Society for Medical Oncology
3-May-2006


Page: 1 2 3

Related medicine news :

1. UCLA, Italian chemists move closer to solving Lou Gehrigs disease mystery
2. Italian doctors get their information on medicines from drug company sales reps
3. Italian public smoking ban leads to fall in hospital heart attack admissions in under 60s
4. UPMC joins Italian government to create $398 million biomedical research center in Sicily
5. Italian law on ART brings problems for doctors and patients
6. Stanford researchers find culprit in aging muscles that heal poorly
7. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
8. Penn researchers discover novel pathway for increasing good cholesterol
9. Theory of facial aging gets a facelift from UT Southwestern researchers
10. UIC researchers to develop new drugs to fight bioterrorism
11. UQ researchers discover some of the oldest forms of life

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... ... August 16, 2017 , ... Ten outstanding teachers in the Greater Houston area ... will win a visit by a Houston Texans player, two tickets to a Texans ... years old can visit texanschecking.com/stars to nominate their favorite teacher with an essay of ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... is collaborating with a New England student to educate the public on the ... in 2016 for launching the first-ever National Concussion Awareness Day. , Brooke is ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... practice partnerships through affiliations and de novo development, today announced Cumberland Skin ... , Cumberland Skin Surgery and Dermatology, with offices in both Hermitage and Lebanon, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Southeastern Telehealth ... grant totaling $975,000, renewing its funding from the Health Resources and Services Administration ... funding marks, the fourth time the HRSA administration has renewed its financial support ...
(Date:8/16/2017)... ... , ... A global leader in the treatment of clubfoot, CURE International ... states—bringing the country one step closer to eliminating clubfoot as a lifelong disability by ... track to enroll 10,000 children in the clubfoot treatment program in this year alone. ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Ind. , Aug. 7, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that its Board of Directors has ... for the third quarter of 2017. ... be paid on or about October 27, 2017 to stockholders ... 22, 2017.  Future declarations of dividends are subject to approval ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
(Date:8/2/2017)... a next-generation full-service pharmacy, has announced the launch of its ... Washington D.C. metropolitan area. CaryRx aims to ... through the convenience of its patient-friendly mobile app. Prescriptions can ... to any location in D.C. ... Washington D.C. ," says Areo Nazari , ...
Breaking Medicine Technology:
Cached News: